224 related articles for article (PubMed ID: 10459815)
1. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
2. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Paul M; Yahav D; Bivas A; Fraser A; Leibovici L
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD005197. PubMed ID: 21069685
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
Ambrose PG; Bhavnani SM; Jones RN
Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C
Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam.
Dornbusch K; Mörtsell E; Göransson E
Chemotherapy; 1990; 36(4):259-67. PubMed ID: 2174761
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
[TBL] [Abstract][Full Text] [Related]
7. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals.
Muller AE; De Winter BCM; Koch BCP
J Antimicrob Chemother; 2024 May; 79(5):1093-1100. PubMed ID: 38507250
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.
Hanberger H
Scand J Infect Dis Suppl; 1992; 81():1-52. PubMed ID: 1322561
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
McGrath BJ; Bailey EM; Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2741-6. PubMed ID: 1482142
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria.
Kuck NA; Petersen PJ; Weiss WJ; Testa RT
J Chemother; 1989 Jun; 1(3):155-61. PubMed ID: 2552030
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
Kern W; Kennedy SL; Sachdeva M; Sande ER; Gunderson D; Täuber MG
Antimicrob Agents Chemother; 1990 May; 34(5):697-701. PubMed ID: 2163241
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Wretlind B; Bergman L; Mentzing LO; Nyström PO; Kihlström E; Bäckstrand B; Skau T
Antimicrob Agents Chemother; 1992 Dec; 36(12):2766-73. PubMed ID: 1336347
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Cabezudo I; Pfaller M; Bale M; Wenzel R
Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
[TBL] [Abstract][Full Text] [Related]
17. Emergence of Resistance in
Custodio MM; Sanchez D; Anderson B; Ryan KL; Walraven C; Mercier RC
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33139285
[TBL] [Abstract][Full Text] [Related]
18. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B.
Lim TP; Lee W; Tan TY; Sasikala S; Teo J; Hsu LY; Tan TT; Syahidah N; Kwa AL
PLoS One; 2011; 6(12):e28177. PubMed ID: 22162759
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibitory and bactericidal activity of cefpiramide and seven antipseudomonal agents against Pseudomonas aeruginosa.
Pfaller M; Bale M; Preston T; Howard W; Koontz F
Diagn Microbiol Infect Dis; 1986 May; 5(1):17-23. PubMed ID: 3086026
[TBL] [Abstract][Full Text] [Related]
20. High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms.
Hengzhuang W; Ciofu O; Yang L; Wu H; Song Z; Oliver A; Høiby N
Antimicrob Agents Chemother; 2013 Jan; 57(1):196-204. PubMed ID: 23089750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
